Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, + Pola-RCHP in patients (pts) with newly diagnosed aggressive B-cell lymphoma (a-BCL): Safety and 12-month (mo) efficacy results.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Marc S. Hoffmann, Grzegorz S. Nowakowski, Michal Kwiatek, Maria Bouzani, Dagmara Zimowska-Curylo, Muhamad Alhaj Moustafa, Alejandro Martin Garcia-Sancho, Juan-Manuel Sancho, Wojciech Jurczak, Arpankumar Patel, Floriane Boucaud, Argyrios Gkasiamis, Mark Kaplan, Arnaud Amzallag, Matt Stokes, Tanvi Jindia, Serena K. Perna, Theodoros Vassilakopoulos
Institutions: The University of Kansas Cancer Center, Mayo Clinic, Poznan University of Medical Sciences, Evangelismos Hospital, Szpital Uniwersytecki w Krakowie, Mayo Clinic in Florida, Universidad de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación Biomédica en Red de Cáncer, Hospital Universitari Germans Trias i Pujol, Bristol-Myers Squibb (United States), National and Kapodistrian University of Athens, Laiko General Hospital of Athens
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162532258
Cites:
Cited by:
Related to: